Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in…
<!-- Name:DistributionId Value:8831080 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->…
Browsing Tag
Gain Therapeutics
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business…
Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted…
Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit
BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites…
Gain Therapeutics Presents Parkinson’s Disease Preclinical Study Results at Society…
BETHESDA, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing…
Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data of Novel Small…
Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in…